

## APC anti-mouse CD8a Antibody

<b>Catalog# / Size</b>	100711 / 25 µg 100712 / 100 µg
<b>Clone</b>	53-6.7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T8, Lyt2, Ly-2
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes <sup>3</sup> . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a <sup>+</sup> cells. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,3</sup> , <i>in vivo</i> and <i>in vitro</i> cell depletion <sup>2,10,15</sup> , inhibition of CD8 T cell proliferation <sup>3</sup> , blocking of cytotoxicity <sup>3,4</sup> , immunohistochemical staining <sup>5,6</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX) <sup>29,30</sup> . Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or <i>in vivo</i> studies (Cat No. 100746).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IHC, IP)</li> <li>2. Hathcock KS. 1991. <i>Current Protocols in Immunology</i>. 3.4.1. (Deplete)</li> <li>3. Takahashi K, <i>et al.</i> 1992. <i>P. Natl. Acad. Sci. USA</i> 89:5557. (Block, IP)</li> <li>4. Ledbetter JA, <i>et al.</i> 1981. <i>J. Exp. Med.</i> 153:1503. (Block)</li> </ol>

5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Ishidome T *et al.* 2017. *EBioMedicine.* 22:89-99 . [PubMed](#)
2. Espinosa-Cueto P, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0182126. [PubMed](#)
3. Glasner A, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12998-w. [PubMed](#)
4. Reismann D, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-01538-9. [PubMed](#)
5. Chatterjee S *et al.* 2017. *Cell metabolism.* 27(1):85-100 . [PubMed](#)
6. Oyarce C, *et al.* 2018. *Front Immunol.* 8:1794. [PubMed](#)
7. Solanki A, *et al.* 2018. *Development.* 145. [PubMed](#)
8. Divan A, *et al.* 2018. *PLoS One.* 13:e0196893. [PubMed](#)
9. Espinosa JR, *et al.* 2018. *Front Immunol.* 9:1371. [PubMed](#)
10. Nam GH, *et al.* 2018. *Nat Commun.* 9:2165. [PubMed](#)
11. Tippimanchai DD, *et al.* 2018. *Oncoimmunology.* 7:e1438105. [PubMed](#)
12. Lee JS *et al.* 2018. *Cell.* 174(6):1559-1570 . [PubMed](#)
13. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503 . [PubMed](#)
14. Gaya M *et al.* 2018. *Cell.* 172(3):517-533 . [PubMed](#)
15. Nakamura K, *et al.* 2018. *Cancer Cell.* 33:634. [PubMed](#)
16. Johnson JL *et al.* 2018. *Immunity.* 48(2):243-257 . [PubMed](#)
17. Logan K Smith *et al.* 2018. *Immunity.* 48(2):299-312 . [PubMed](#)
18. Cong J *et al.* 2018. *Cell metabolism.* 28(2):243-255 . [PubMed](#)
19. Chen S *et al.* 2018. *Cell reports.* 25(7):1729-1740 . [PubMed](#)
20. Wang D, *et al.* 2018. *Immunity.* 48:659. [PubMed](#)
21. Ren W, *et al.* 2018. *Mucosal Immunol.* 12:531. [PubMed](#)
22. Konishi Y, *et al.* 2018. *iScience.* 10:98. [PubMed](#)
23. Chen Z, *et al.* 2019. *J Exp Med.* 216:152. [PubMed](#)
24. Chakrabarti J, *et al.* 2018. *Oncotarget.* 9:37439. [PubMed](#)
25. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283 . [PubMed](#)
26. Tran L, *et al.* 2017. *Cancer Immunol Res.* 5:1141. [PubMed](#)
27. Koliaraki V *et al.* 2019. *Cell reports.* 26(3):536-545 . [PubMed](#)
28. Funk KE, *et al.* 2019. *J Neuroinflammation.* 16:22. [PubMed](#)
29. Liu J, *et al.* 2019. *J Exp Med.* 216:656. [PubMed](#)
30. Li Y, *et al.* 2019. *Oncol Rep.* 41:2679. [PubMed](#)
31. Miska J *et al.* 2019. *Cell reports.* 27(1):226-237 . [PubMed](#)
32. Misumi I *et al.* 2019. *Cell Rep.* 27(2):514-524 . [PubMed](#)
33. Misumi I *et al.* 2019. *Cell Rep.* 27(5):1387-1396 . [PubMed](#)
34. Hu J, *et al.* 2019. *Mol Ther Nucleic Acids.* 16:650. [PubMed](#)
35. Luo Y *et al.* 2019. *Cell reports.* 26(7):1869-1879 . [PubMed](#)
36. Spangenberg E, *et al.* 2019. *Nat Commun.* 10:3758. [PubMed](#)
37. Schuster M, *et al.* 2017. *J Immunol.* 199:920. [PubMed](#)
38. Zhang F, *et al.* 2019. *Nat Commun.* 10:3974. [PubMed](#)
39. Budida R, *et al.* 2017. *Eur J Immunol.* 47:1819. [PubMed](#)
40. Lin YH, *et al.* 2018. *Cancer Immunol Res.* 0.25. [PubMed](#)
41. Schuster M, *et al.* 2019. *Front Immunol.* 10:1583. [PubMed](#)
42. Uchimura T *et al.* 2018. *Immunity.* 49(6):1049-1061 . [PubMed](#)
43. Paris J *et al.* 2019. *Cell Stem Cell.* 25(1):137-148 . [PubMed](#)
44. Song C, *et al.* 2019. *Nat Commun.* 10:3745. [PubMed](#)
45. Takeda Y, *et al.* 2018. *Innate Immun.* 24:323. [PubMed](#)
46. Li X, *et al.* 2017. *Front Immunol.* 8:1186. [PubMed](#)
47. Liu WL, *et al.* 2019. *Nat Commun.* 10:3199. [PubMed](#)
48. Li W, *et al.* 2019. *Nat Commun.* 10:3349. [PubMed](#)
49. Liu D *et al.* 2019. *Immunity.* 51(1):64-76 . [PubMed](#)
50. Zhang F, *et al.* 2019. *Immunity.* 50:738. [PubMed](#)
51. Li X *et al.* 2019. *Immunity.* 50(3):576-590 . [PubMed](#)

52. Riffelmacher T *et al.* 2017. *Immunity*. 47(3):466-480 . [PubMed](#)
53. Matsuo K, *et al.* 2018. *J Immunol*. 200:800. [PubMed](#)
54. Caronni N, *et al.* 2018. *Cancer Res*. 78:1685. [PubMed](#)
55. Lee JH, *et al.* 2018. *Transgenic Res*. 27:241. [PubMed](#)
56. Al-Zaher AA, *et al.* 2018. *Mol Ther Oncolytics*. 0.376388889. [PubMed](#)
57. Zhang J, *et al.* 2018. *Oncoimmunology*. 7:e1461301. [PubMed](#)
58. O'Malley G, *et al.* 2018. *Cancer Immunol Res*. 1.240277778. [PubMed](#)
59. Leal AS, *et al.* 2019. *Sci Rep*. 5.286111111. [PubMed](#)
60. Lin W, *et al.* 2019. *EBioMedicine*. 49:133. [PubMed](#)
61. Gupta SS, *et al.* 2019. *Cell Rep*. 29:1862. [PubMed](#)
62. Takaku S, *et al.* 2020. *Integr Cancer Ther*. 19:1534735419900798. [PubMed](#)
63. Morelli AE, *et al.* 2020. *Cell Rep*. 30:3448. [PubMed](#)
64. Ulaganathan VK, *et al.* 2020. *Sci Rep*. 10:8453. [PubMed](#)
65. Yoshida H, *et al.* 2019. *Cell*. 176:897. [PubMed](#)
66. Han P, *et al.* 2020. *Sci Adv*. 6:eaaz1580. [PubMed](#)
67. Soldevilla MM, *et al.* 2019. *Mol Ther*. 27:1878. [PubMed](#)
68. Chao Y, *et al.* 2020. *Sci Adv*. 6:eaaz4204. [PubMed](#)
69. Jiang W, *et al.* 2017. *Sci Rep*. 7:6501. [PubMed](#)
70. Kataru RP, *et al.* 2019. *Cancer Immunol Res*. 7:1345. [PubMed](#)
71. Xu X, *et al.* 2020. *Chin Med*. 15:33. [PubMed](#)
72. Riley JS, *et al.* 2020. *Blood Adv*. 4:1102. [PubMed](#)
73. Demircioglu F, *et al.* 2020. *Nat Commun*. 11:1290. [PubMed](#)
74. Maluski M, *et al.* 2019. *J Clin Invest*. 129:5108. [PubMed](#)
75. Schadt L, *et al.* 2020. *Cell Reports*. 29(5):1236-1248.e7.. [PubMed](#)
76. Bai C, *et al.* 2020. *Mol Ther Oncolytics*. 17:9. [PubMed](#)
77. Alikhanyan K, *et al.* 2020. *Immun Inflamm Dis*. 8:181. [PubMed](#)
78. Wang J, *et al.* 2020. *J Hematol Oncol*. 0.610416667. [PubMed](#)
79. Brummer G, *et al.* 2020. *Oncogene*. 39:2275. [PubMed](#)
80. Zheng Z, *et al.* 2020. *Cell Death Dis*. 0.684722222. [PubMed](#)
81. Horiguchi H, *et al.* 2019. *Genes Dev*. 33:1641. [PubMed](#)
82. Zhang NN, *et al.* 2020. *Cell*. 182(5):1271-1283. [PubMed](#)
83. Lu Y, *et al.* 2020. *Cell*. 180(6):1081-1097. [PubMed](#)
84. Blumenthal D, *et al.* 2020. *eLife*. 9:e55995.. [PubMed](#)
85. Chakraborty P, *et al.* 2020. *Cell Reports*. 28(7):1879-1893.e7.. [PubMed](#)
86. Zhang C, *et al.* 2020. *Cell Metabolism*. 31(1):148-161.e5.. [PubMed](#)
87. Mohamed E, *et al.* 2020. *Immunity*. 52(4):668-682.e7.. [PubMed](#)
88. Xu H, *et al.* 2020. *Immunity*. 51(4):696-708.e9.. [PubMed](#)
89. Miranda AC, *et al.* 2020. *Oncoimmunology*. 9:1760685. [PubMed](#)
90. Medyouf H, *et al.* 2010. *Blood*. 115:1175. [PubMed](#)
91. Sun S, *et al.* 2013. *J Immunol*. 190:6209. [PubMed](#)
92. Guo H, *et al.* 2014. *J Leukoc Biol*. 96:419. [PubMed](#)
93. Tassi I, *et al.* 2014. *J Immunol*. 193:4303. [PubMed](#)
94. Gibbins J, *et al.* 2014. *Blood*. 124:2953. [PubMed](#)
95. Shade K, *et al.* 2015. *J Exp Med*. 212:457. [PubMed](#)
96. Sasaki Y, *et al.* 2015. *PLoS One*. 10: 0131176. [PubMed](#)
97. Teo T, *et al.* 2015. *J Virol*. 89: 7955-7969. [PubMed](#)
98. Yin Q, *et al.* 2015. *PLoS One*. 10: 0137808. [PubMed](#)
99. Ku C, *et al.* 2015. *Genes Dev*. 29: 1930-1941. [PubMed](#)
100. Chen S, *et al.* 2015. *Cancer Res*. 7: 519-531. [PubMed](#)
101. Poczobutt J, *et al.* 2016. *J Immunol*. 196: 891 - 901. [PubMed](#)
102. Cook KD, *et al.* 2015. *Immunity*. 43:703-714. [PubMed](#)
103. Pelly V, *et al.* 2016. *Mucosal Immunol*. 10.1038/mi.2016.4. [PubMed](#)
104. Ma Z, *et al.* 2016. *Clin Cancer Res*. 22: 2969 - 2980. [PubMed](#)
105. Iwasaki Y, *et al.* 2016. *PLoS One*. 11: 0158282. [PubMed](#)
106. Vieyra-Garcia P, *et al.* 2016. *Clin Cancer Res*. 22: 3328 - 3339. [PubMed](#)
107. Latasa C, *et al.* 2016. *PLoS One*. 11: 0161216. [PubMed](#)
108. Matsumura K, *et al.* 2016. *J Immunol*. 197: 3233 - 3244. [PubMed](#)
109. Chen Q, *et al.* 2016. *Nat Commun*. 7:13193. [PubMed](#)
110. Vidy A, *et al.* 2016. *PLoS One*. 11:e0165361. [PubMed](#)
111. Felker A, Croy B 2016. *J Leukoc Biol*. 100: 645 - 655. [PubMed](#)
112. Wagner V, *et al.* 2016. *Sci Transl Med*. 8: 366ra164. [PubMed](#)
113. Eriksson E, *et al.* 2016. *Gene Ther*. 10.1038/gt.2016.80. [PubMed](#)
114. Swanson P, *et al.* 2016. *PLoS Pathog*. 12:e1006022. [PubMed](#)
115. Kramer K, *et al.* 2017. *Mol Ther*. 25(1):62-70. [PubMed](#)
116. Wu L, *et al.* 2020. *Cell Rep*. 33:108327. [PubMed](#)
117. Zheng DW, *et al.* 2020. *Nat Commun*. 3.865972222. [PubMed](#)
118. Holokai L, *et al.* 2020. *Cancers (Basel)*. 12:00. [PubMed](#)
119. Choi JG, *et al.* 2020. *Front Immunol*. 11:598556. [PubMed](#)
120. Galeano Nio JL, *et al.* 2020. *eLife*. 9:00. [PubMed](#)
121. Gong N, *et al.* 2020. *Nat Nanotechnol*. 1.35625. [PubMed](#)
122. Leach SM, *et al.* 2020. *Cell Rep*. 33:108337. [PubMed](#)
123. Yin X, *et al.* 2020. *Cell Rep*. 33:108278. [PubMed](#)
124. Wanner-Seleznik GM, *et al.* 2020. *Immunohorizons*. 0.644444444. [PubMed](#)
125. Hoefflin R, *et al.* 2020. *Nat Commun*. 3.313194444. [PubMed](#)
126. Yi X, *et al.* 2020. *Sci Adv*. 6:eaba3546. [PubMed](#)
127. Ukidve A, *et al.* 2020. *Proc Natl Acad Sci U S A*. 117:17727. [PubMed](#)
128. Wang H, *et al.* 2020. *Nat Mater*. 1.655555556. [PubMed](#)
129. He C, *et al.* 2020. *Clin Transl Med*. 10:e39. [PubMed](#)
130. Bayik D, *et al.* 2020. *Cancer Discov*. 1.256944444. [PubMed](#)
131. Elahi S, *et al.* 2020. *Stem Cell Res*. 43:101710. [PubMed](#)

132. Aegerter H, *et al.* 2020. *Nat Immunol.* 0.975694444. [PubMed](#)
133. Chang YS, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
134. Zheng H, *et al.* 2021. *Frontiers in Cell and Developmental Biology.* 9:641527. [PubMed](#)
135. Tartey S, *et al.* 2021. *Cancer Research.* 81(9):2358-2372. [PubMed](#)
136. Nahrendorf W, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
137. Lebratti T, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
138. Oguri Y, *et al.* 2020. *Cell.* 182(3):563-577.e20. [PubMed](#)
139. Alexandre YO, *et al.* 2020. *Cell Reports.* 33(13):108567. [PubMed](#)
140. Lu C, *et al.* 2020. *Cancer Cell.* 39(1):96-108.e6. [PubMed](#)
141. Shannon JP, *et al.* 2021. *Immunity.* 54(2):276-290.e5. [PubMed](#)
142. Han C, *et al.* 2021. *Cell Reports.* 34(6):108706. [PubMed](#)
143. Chen R, *et al.* 2021. *Cell Reports.* 34(7):108751. [PubMed](#)
144. Zeng W, *et al.* 2021. *STAR Protocols.* 2(1):100361. [PubMed](#)
145. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
146. Dallari S, *et al.* 2021. *Cell Host Microbe.* 29(6):1014-1029.e8. [PubMed](#)
147. Liu Y, *et al.* 2021. *Cell Metabolism.* 33(6):1221-1233.e11. [PubMed](#)
148. Uzhachenko RV, *et al.* 2021. *Cell Reports.* 35(1):108944. [PubMed](#)
149. Mitchell JE, *et al.* 2021. *Cell Reports.* 35(2):108966. [PubMed](#)
150. Paiva RA, *et al.* 2021. *Cell Reports.* 35(2):108967. [PubMed](#)
151. Vaena S, *et al.* 2021. *Cell Reports.* 35(5):109076. [PubMed](#)
152. Christian LS, *et al.* 2021. *Cell Reports.* 35(6):109118. [PubMed](#)
153. Nanou A, *et al.* 2021. *Cell Reports.* 35(8):109168. [PubMed](#)
154. Dong L, *et al.* 2021. *Cancer Cell.* . [PubMed](#)

**RRID** AB\_312750 (BioLegend Cat. No. 100711)  
 AB\_312751 (BioLegend Cat. No. 100712)

## Antigen Details

<b>Structure</b>	Ig superfamily, CD8 $\alpha$ chain, 34 kD
<b>Distribution</b>	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
<b>Function</b>	Co-receptor for TCR
<b>Ligand/Receptor</b>	MHC class I molecule
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Zamoyska R. 1994. <i>Immunity</i> 1:243.</li> <li>3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.</li> </ol>
<b>Gene ID</b>	<a href="#">12525</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GolnVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

## Product Data



C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587